中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 7
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(7): 1619-1625

Association of nonalcoholic fatty liver disease with the risk of colorectal adenoma and colorectal cancer: A Meta-analysis

DOI: 10.3969/j.issn.1001-5256.2021.07.028
  • a.

    Department of Gastroenterology, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China

  • b.

    Experimental Center of Science and Research, First Hospital of Shanxi Medical University, Shanxi Medical University, Taiyuan 030001, China

  • c.

    Institute of Liver Disease and Organ Transplantation, Shanxi Medical University, Taiyuan 030001, China

Research funding:

The Funding of Scientific and Technological Development with Central Government Guiding Local (Department of Science and Technology of Shanxi Province) (YDZX20201400001965)

  • Received Date: 2020-12-12
  • Accepted Date: 2021-02-04
  • Published Date: 2021-07-20
    Abstract
  •   Objective  To systematically evaluate the association of the presence and severity of nonalcoholic fatty liver disease (NAFLD) with the risk of colorectal adenoma (CRA) and colorectal cancer (CRC).  Methods  PubMed, Embase, Web of Science, The Cochrane Library, CNKI, Wanfang Data, and VIP databases were searched for Chinese and English articles on the association of NAFLD with CRA and CRC published up to December 2019. Secondary screening, quality assessment, and data extraction were performed according to inclusion and exclusion criteria, and RevMan 5.3 software was used to perform the meta-analysis.  Results  A total of 3 longitudinal cohort studies and 18 cross-sectional studies were included, with 130 271 subjects in total. The meta-analysis showed that NAFLD patients had an increased risk of CRA (adjusted odds ratio [aOR]=1.27, 95% confidence interval [CI]: 1.18-1.36, P < 0.000 01) and advanced CRA/CRC (aOR=1.45, 95%CI: 1.27-1.65, P < 0.000 01). The severity of NAFLD affected such association, and patients with nonalcoholic steatohepatitis and/or advanced liver fibrosis had a significant increase in the risk of CRA/CRC (aOR=1.93, 95%CI: 1.61-2.31, P < 0.000 01).  Conclusion  The presence of NAFLD is associated with an increased risk of CRA and CRC, and the higher the severity of NAFLD, the higher the risk of CRA and CRC.

     

    • FullText(HTML)
  • loading
    • References(33)
  • [1]
    BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
    [2]
    LESLIE A, CAREY FA, PRATT NR, et al. The colorectal adenoma-carcinoma sequence[J]. Br J Surg, 2002, 89(7): 845-860. DOI: 10.1046/j.1365-2168.2002.02120.x.
    [3]
    AHMED RL, SCHMITZ KH, ANDERSON KE, et al. The metabolic syndrome and risk of incident colorectal cancer[J]. Cancer, 2006, 107(1): 28-36. DOI: 10.1002/cncr.21950.
    [4]
    TAVANI A, BRAVI F, BOSETTI C, et al. Diabetes mellitus and subsite-specific colorectal cancer risks in the Iowa Women's Health Study[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(9): 2277. DOI: 10.1158/1055-9965.EPI-05-0331.
    [5]
    BARDOU M, BARKUN AN, MARTEL M. Obesity and colorectal cancer[J]. Gut, 2013, 62(6): 933-947. DOI: 10.1136/gutjnl-2013-304701.
    [6]
    LONARDO A, NASCIMBENI F, MANTOVANI A, et al. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?[J]. J Hepatol, 2018, 68(2): 335-352. DOI: 10.1016/j.jhep.2017.09.021.
    [7]
    CHO Y, LIM SK, JOO SK, et al. Nonalcoholic steatohepatitis is associated with a higher risk of advanced colorectal neoplasm[J]. Liver Int, 2019, 39(9): 1722-1731. DOI: 10.1111/liv.14163.
    [8]
    BASYIGIT S, UZMAN M, KEFELI A, et al. Absence of non-alcoholic fatty liver disease in the presence of insulin resistance is a strong predictor for colorectal carcinoma[J]. Int J Clin Exp Med, 2015, 8(10): 18601-18610. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694373/
    [9]
    HWANG ST, CHO YK, PARK JH, et al. Relationship of non-alcoholic fatty liver disease to colorectal adenomatous polyps[J]. J Gastroenterol Hepatol, 2010, 25(3): 562-567. DOI: 10.1111/j.1440-1746.2009.06117.x.
    [10]
    STADLMAYR A, AIGNER E, STEGER B, et al. Nonalcoholic fatty liver disease: An independent risk factor for colorectal neoplasia[J]. J Intern Med, 2011, 270(1): 41-49. DOI: 10.1111/j.1365-2796.2011.02377.x.
    [11]
    TOUZIN NT, BUSH KN, WILLIAMS CD, et al. Prevalence of colonic adenomas in patients with nonalcoholic fatty liver disease[J]. Therap Adv Gastroenterol, 2011, 4(3): 169-176. DOI: 10.1177/1756283X11402118.
    [12]
    WONG VW, WONG GL, TSANG SW, et al. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis[J]. Gut, 2011, 60(6): 829-836. DOI: 10.1136/gut.2011.237974.
    [13]
    LEE YI, LIM YS, PARK HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study[J]. J Gastroenterol Hepatol, 2012, 27(1): 91-95. DOI: 10.1111/j.1440-1746.2011.06816.x.
    [14]
    HUANG KW, LEU HB, WANG YJ, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy[J]. Colorectal Dis, 2013, 15(7): 830-835. DOI: 10.1111/codi.12172.
    [15]
    LIN XF, SHI KQ, YOU J, et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: A large study[J]. Mol Biol Rep, 2014, 41(5): 2989-2997. DOI: 10.1007/s11033-014-3157-y.
    [16]
    BHATT BD, LUKOSE T, SIEGEL AB, et al. Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation[J]. J Gastrointest Oncol, 2015, 6(5): 459-468. DOI: 10.3978/j.issn.2078-6891.2015.050.
    [17]
    CHEN QF, ZHOU XD, SUN YJ, et al. Sex-influenced association of non-alcoholic fatty liver disease with colorectal adenomatous and hyperplastic polyps[J]. World J Gastroenterol, 2017, 23(28): 5206-5215. DOI: 10.3748/wjg.v23.i28.5206.
    [18]
    KIM JH, CHO KI, KIM YA, et al. Elevated neutrophil-to-lymphocyte ratio in metabolic syndrome is associated with increased risk of colorectal adenoma[J]. Metab Syndr Relat Disord, 2017, 15(8): 393-399. DOI: 10.1089/met.2017.0041.
    [19]
    ZE EY, KIM BJ, JUN DH, et al. The fatty liver index: A simple and accurate predictor of colorectal adenoma in an average-risk population[J]. Dis Colon Rectum, 2018, 61(1): 36-42. DOI: 10.1097/DCR.0000000000000973.
    [20]
    BLACKETT JW, VERNA EC, LEBWOHL B. Increased prevalence of colorectal adenomas in patients with nonalcoholic fatty liver disease: A cross-sectional study[J]. Dig Dis, 2020, 38(3): 222-230. DOI: 10.1159/000502684.
    [21]
    KIM MC, PARK JG, JANG BI, et al. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease[J]. Medicine (Baltimore), 2019, 98(6): e14139. DOI: 10.1097/MD.0000000000014139.
    [22]
    LI Y, LIU S, GAO Y, et al. Association between NAFLD and risk of colorectal adenoma in Chinese han population[J]. J Clin Transl Hepatol, 2019, 7(2): 99-105. DOI: 10.14218/JCTH.2019.00010.
    [23]
    AHN JS, SINN DH, MIN YW, et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia[J]. Aliment Pharmacol Ther, 2017, 45(2): 345-353. DOI: 10.1111/apt.13866.
    [24]
    LEE T, YUN KE, CHANG Y, et al. Risk of colorectal neoplasia according to fatty liver severity and presence of gall bladder polyps[J]. Dig Dis Sci, 2016, 61(1): 317-324. DOI: 10.1007/s10620-015-3873-8.
    [25]
    YANG YJ, BANG CS, SHIN SP, et al. Clinical impact of non-alcoholic fatty liver disease on the occurrence of colorectal neoplasm: Propensity score matching analysis[J]. PLoS One, 2017, 12(8): e0182014. DOI: 10.1371/journal.pone.0182014.
    [26]
    PAN S, HONG W, WU W, et al. The relationship of nonalcoholic fatty liver disease and metabolic syndrome for colonoscopy colorectal neoplasm[J]. Medicine (Baltimore), 2017, 96(2): e5809. DOI: 10.1097/MD.0000000000005809.
    [27]
    KIM GA, LEE HC, CHOE J, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate[J]. J Hepatol, 2017. DOI: 10.1016/j.jhep.2017.09.012.
    [28]
    KANG HW, KIM D, KIM HJ, et al. Visceral obesity and insulin resistance as risk factors for colorectal adenoma: A cross-sectional, case-control study[J]. Am J Gastroenterol, 2010, 105(1): 178-187. DOI: 10.1038/ajg.2009.541.
    [29]
    CUSI K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis[J]. Clin Liver Dis, 2009, 13(4): 545-563. DOI: 10.1016/j.cld.2009.07.009.
    [30]
    WEI EK, GIOVANNUCCI E, FUCHS CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study[J]. J Natl Cancer Inst, 2005, 97(22): 1688-1694. DOI: 10.1093/jnci/dji376.
    [31]
    BUZZETTI E, PINZANI M, TSOCHATZIS EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)[J]. Metabolism, 2016, 65(8): 1038-1048. DOI: 10.1016/j.metabol.2015.12.012.
    [32]
    HYOGO H, YAMAGISHI S, IWAMOTO K, et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis[J]. J Gastroenterol Hepatol, 2007, 22(7): 1112-1119. DOI: 10.1111/j.1440-1746.2007.04943.x.
    [33]
    ABIRU S, MIGITA K, MAEDA Y, et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis[J]. Liver Int, 2006, 26(1): 39-45. DOI: 10.1111/j.1478-3231.2005.01191.x.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(10)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (671) PDF downloads(58) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return